treatment for Pulmonary Hypertension


(Novel Oral Anticoagulants) or DOACs (Direct Oral Anticoagulants)

This new group of medicines is becoming increasingly prescribed to PH patients because they have some very clear advantages over warfarin;

  • No need for regular blood test monitoring
  • Standardised dosing
  • Quicker onset of action
  • No need for bridging with injections when interrupting anticoagulation for an invasive test or procedure.

However on the down side;

  • We do not have long-term experience as yet and there have been no specific studies in PH.
  • As they are removed from the body by the kidneys, anyone with renal (kidney) impairment may not be suitable for a NOAC/DOAC.
  • Not all GPs are able to prescribe NOAC/DOACs for PH yet.

Currently there are four NOAC/DOACs available in the UK;

  • Rivaroxaban
  • Apixaban
  • Edoxaban
  • Dabigatran

The decision regarding which will be most appropriate can be made by your GP, local anticoagulation clinic or PH specialist centre.

DOACs work in a slightly different way to warfarin, however the precautions mentioned regarding warfarin will still apply.

Last medically reviewed: July, 2016 • Due for review: July, 2019